Price T Rowe Associates Inc. MD lowered its holdings in shares of Athersys, Inc. (NASDAQ:ATHX) by 49.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 161,292 shares of the biopharmaceutical company’s stock after selling 157,403 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Athersys were worth $282,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. grew its holdings in Athersys by 3.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 435,209 shares of the biopharmaceutical company’s stock valued at $762,000 after buying an additional 12,664 shares in the last quarter. LPL Financial LLC increased its position in Athersys by 10.0% during the 4th quarter. LPL Financial LLC now owns 84,086 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 7,675 shares during the period. The Manufacturers Life Insurance Company raised its stake in Athersys by 8.2% in the fourth quarter. The Manufacturers Life Insurance Company now owns 109,363 shares of the biopharmaceutical company’s stock worth $191,000 after buying an additional 8,270 shares in the last quarter. Teacher Retirement System of Texas lifted its position in shares of Athersys by 60.0% during the fourth quarter. Teacher Retirement System of Texas now owns 17,237 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 6,463 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Athersys by 7.1% during the fourth quarter. Rhumbline Advisers now owns 191,038 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 12,650 shares in the last quarter. Institutional investors and hedge funds own 27.87% of the company’s stock.
Separately, Zacks Investment Research upgraded shares of Athersys from a “sell” rating to a “hold” rating in a research report on Tuesday, March 30th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $9.00.
Athersys (NASDAQ:ATHX) last issued its earnings results on Wednesday, March 24th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). On average, sell-side analysts anticipate that Athersys, Inc. will post -0.43 EPS for the current fiscal year.
In other Athersys news, CEO William Lehmann, Jr. sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, March 18th. The stock was sold at an average price of $1.91, for a total transaction of $47,750.00. Following the completion of the sale, the chief executive officer now directly owns 443,836 shares of the company’s stock, valued at approximately $847,726.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders sold 40,000 shares of company stock valued at $77,300. 12.60% of the stock is owned by insiders.
Athersys Company Profile
Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
Featured Article: What strategies should day traders use to execute a trade?
Want to see what other hedge funds are holding ATHX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athersys, Inc. (NASDAQ:ATHX).
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.